Clinuvel gets green light

By Dylan Bushell-Embling
Wednesday, 11 June, 2008


Clinuvel Pharmaceuticals (ASX: CUV) has received ethical approval to begin Phase II testing of its solar urticaria (SU) treatment.

SU is a severe but rare disease that effects less than one per cent of the population. An SU sufferer's skin becomes badly sunburned after limited contact with the sun.

More prolonged exposure can cause red welts to appear on the skin, and can cause fainting, nausea and headaches. Symptoms last up to 24 hours.

Clinuvel hopes its new photo-receptive drug, CUV1647, can prove an effective preventative treatment for SU sufferers.

CUV1647 is expected to have a number of applications in the treatment of human diseases caused by abnormal quantities of melanin in the skin.

The trial will be conducted at Hope Hospital in Manchester in the UK.

Related News

Paradigm receives ethics approval for osteoarthritis trial

Paradigm Biopharmaceuticals has received ethics approval for its Phase 2b clinical trial to...

Genome editing, OCT4 and human embryo development

UK scientists have used CRISPR-CAS9 to study the role of the OCT4 protein in early human embryo...

Personalised medicine trial for childhood cancers

Personalised medicine for childhood cancers in Australia is now one step closer, following the...


  • All content Copyright © 2017 Westwick-Farrow Pty Ltd